Evidence map›Paper›PMID 12358603›Full record

ArticleThe Biochemical journal2003

Factor VII mutant V154G models a zymogen-like form of factor VIIa.

Raffaella Toso, Francesco Bernardi, Theresa Tidd, Mirko Pinotti, Rodney M Camire, Giovanna Marchetti, Katherine A High, Eleanor S Pollak

Open access · greenAbstract read
In one paragraph

Article in The Biochemical journal, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Raffaella TosoDepartment of Biochemistry and Molecular Biology, University of Ferrara, Via Luigi Borsari, 46 Ferrara 44100, Italy. r-toso@hotmail.com
Francesco Bernardi
Theresa Tidd
Mirko Pinotti
Rodney M Camire
Giovanna Marchetti
Katherine A High
Eleanor S Pollak
Children's Hospital of Philadelphia · USUniversity of Ferrara · ITHospital of the University of Pennsylvania · US

Funding

REGULATION OF EXPRESSION OF COAGULATION FACTOR VIIK08HL003661 · NHLBI · CHILDREN'S HOSPITAL OF PHILADELPHIA · PI POLLAK, ELEANOR · 1997 to 2001
$244k
NHLBI NIH HHS HL-K0803661Telethon GGP02182
6 · The paper itself

Abstract

Proteolytic cleavage of the peptide bond between Arg(152) and Ile(153) converts the procoagulant protein Factor VII (FVII) to an activated two-chain form (FVIIa). The formation of a salt bridge between Ile(153) and Asp(343) drives the conversion of FVIIa from being zymogen-like to the active form. In the present paper, we describe the novel FVII mutant V154G (Val(154)-->Gly mutation; residue 17 in the chymotrypsin numbering system), found in three FVII-deficient patients, which models a zymogen-like form of FVIIa. Recombinant V154G FVIIa, although normally cleaved, shows markedly reduced activity towards peptidyl substrate and undetectable activity towards macromolecular substrates. Susceptibility of Ile(153) to chemical modification, in either the presence or the absence of tissue factor (TF), suggests that the reduced V154G FVIIa activity is caused by impaired salt-bridge formation, thus resulting in a zymogen-like FVIIa form. The TF-mediated protection from chemical modification of V154A indicated that Gly(154) is responsible for this peculiar feature, and suggests that this region, proximal to the heavy chain N-terminus, is directly involved in the conversion of FVII into FVIIa. V154G FVII was exploited to study the FVII-TF interaction, together with three additional FVII variants that were expressed to serve as models for different FVII forms. The comparison of binding affinities of full-length TF after relipidation in L-alpha-phosphatidylcholine for the zymogen FVII (Arg(152)-->Gln, K (d)=1.04+/-0.27 nM), inactive FVIIa (Ser(344)-->Ala, K (d)=0.27+/-0.06 nM) and a zymogen-like FVIIa (V154G, K (d)=1.15+/-0.16 nM) supports the hypothesis that preferential binding of TF to active FVIIa is insufficient to drive the 10(5)-fold enhancement of FVIIa activity. In addition, the inability of V154G FVIIa to accommodate an inhibitor in the active site, indicating an improperly shaped specificity pocket, would explain the low activity of the zymogen-like form of FVIIa, which is predominant in the absence of TF.

Indexed as

Point MutationAlanineAmino Acid Chloromethyl KetonesBinding SitesEnzyme PrecursorsFactor VIIFactor VIIaHumansIsoleucineProtein ConformationSerine Proteinase InhibitorsThromboplastinValineAlanineAmino Acid Chloromethyl KetonesEnzyme PrecursorsFactor VIIFactor VIIaIsoleucinephenylalanyl-prolyl-arginine-chloromethyl ketoneSerine Proteinase InhibitorsThromboplastinValine

Identifiers

PMID12358603
PMCPMC1223097
OpenAlexW2032445051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.